Viveve Announces Positive Primary Efficacy Data from its SUI Feasibility Study and Positive Preclinical Outcomes that Support the Company's New Sham Tip for Pivotal PURSUIT Trial - BioSpace
[unable to retrieve full-text content] Progress on Cardiovascular Disease Care in the U.S. Has Stalled Despite Treatment Advances, New Report Finds The Harvard Crimson
Comments
Post a Comment